Articles In Press                   Back to the articles list | Back to browse issues page

Ethics code: IR.IAU.Z.REC.1396,101

XML Print

Assessment of Serum Expression of lncRNA MHENCR, miR-425, and PI3K in Iranian Patients with Melanoma
Fatemeh Shahmohamadi1 , Zohre Sadeghi2 , Zahra Davoudi *3
1- National center for health insurance research, Tehran, Iran.
2- Cellular and Molecular Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan, Iran.
3- Department of Medical Biotechnology, Zanjan University of Medical Science, Zanjan, Iran , davoudibiotech@gmail.com
Abstract:   (459 Views)
Background and Objective: Melanoma is recognized as one of the most aggressive types of human cancer, arising from the uncontrolled growth of melanocytes. Recent research has emphasized the crucial role of non-coding RNAs in the development and progression of cancer. In this study, we investigated the expression patterns of lncRNA MHENCR, miR-425 and PI3K in 17 melanoma samples. Methods:  In present study, we used real-time PCR to assess the expression levels of lncRNA MHENCR, miR-425 and PI3K in the serum of Iranian melanoma patients. β-actin and GAPDH were both used as controls.
Results: Real-time PCR analysis showed that the expression of lncRNA MHENCR in the serum samples of melanoma patients was increased 1.23-fold compared to the control group (p < 0.05),  while the expression of miR-425 and PI3K was decreased by 0.828-fold and 0.795-fold, respectively (p < 0.05).
Conclusion: Changes in the expression of MHENCR, miR-425 and PI3K highlight their key roles in melanoma-related regulatory pathways and their potential as diagnostic, prognostic, and therapeutic targets.
 
Keywords: Melanoma, MicroRNA, lncRNA, miR-425, PI3K.
     
Type of Study: Original Research Article | Subject: Life Science
Received: 2025/10/25 | Accepted: 2026/06/22
References
1. Liu C, Liu X, Hu L, Li X, Xin H, Zhu S. Global, regional, and national burden of cutaneous malignant melanoma from 1990 to 2021 and prediction to 2045. Front Oncol. 2024;14:1512942. [DOI:10.3389/fonc.2024.1512942] [PMID] [PMCID]
2. Roky AH, Islam MM, Ahasan AMF, Mostaq MS, Mahmud MZ, Amin MN, et al. Overview of skin cancer types and prevalence rates across continents. Cancer Pathog Ther. 2025;3(02):89-100. [DOI:10.1016/j.cpt.2024.08.002] [PMID] [PMCID]
3. Druskovich C, Kelley J, Aubrey J, Palladino L, Wright GP. A review of melanoma subtypes: genetic and treatment considerations. J Surg Oncol. 2025;131(3):356-64. [DOI:10.1002/jso.27953] [PMID] [PMCID]
4. Naik PP. Cutaneous malignant melanoma: a review of early diagnosis and management. World J Oncol. 2021;12(1):7. [DOI:10.14740/wjon1349] [PMID] [PMCID]
5. Rakhshan A, Moradi A, Masoudi E. Melanoma in Iranian childhood and adolescence: An Analysis of 14 Patients. Int J Cancer Manage. 2023;16(1). [DOI:10.5812/ijcm-121873]
6. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522-31. [DOI:10.1038/nrg1379] [PMID] []
7. Hudder A, Novak RF. MiRNAs: effectors of environmental influences on gene expression and disease. Toxicol Sci. 2008;103(2):228-40. [DOI:10.1093/toxsci/kfn033] [PMID] [PMCID]
8. Sevignani C, Calin GA, Siracusa LD, Croce CM. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome. 2006;17(3):189-202. [DOI:10.1007/s00335-005-0066-3] [PMID] [PMCID]
9. Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Res. 2016;76(13):3666-70. [DOI:10.1158/0008-5472.CAN-16-0359] [PMID] [PMCID]
10. Otmani K, Lewalle P. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Front Oncol. 2021;11:708765. [DOI:10.3389/fonc.2021.708765] [PMID] [PMCID]
11. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009;28(3):369-378. [DOI:10.1007/s10555-009-9188-5] [PMID]
12. Cruz ATD, Jasiulionis MG. miRNAs and melanoma: how are they connected? Dermatol Res Pract. 2012;2012:528345. [DOI:10.1155/2012/528345] [PMID] [PMCID]
13. Segura MF, Greenwald HS, Hanniford D, Osman I, Hernando E. MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis. 2012;33(10):1823-32. [DOI:10.1093/carcin/bgs205] [PMID] [PMCID]
14. Fattore L, Costantini S, Malpicci D, Ruggiero CF, Ascierto PA, Croce CM, et al. MicroRNAs in melanoma development and resistance to target therapy. Oncotarget. 2017;8(13):22262. [DOI:10.18632/oncotarget.14763] [PMID] [PMCID]
15. Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen LL, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24(6):430-47. [DOI:10.1038/s41580-022-00566-8] [PMID]
16. Nikoofar P, Azodian Ghajar H. Long non-coding RNAs: hidden regulators of cancer. Transl Res Urol. 2023;5(1):1-3.
17. Wozniak M, Czyz M. The functional role of long non-coding RNAs in melanoma. Cancers. 2021;13(19):4848. [DOI:10.3390/cancers13194848] [PMID] [PMCID]
18. Montico B, Giurato G, Pecoraro G, Salvati A, Covre A, Colizzi F, et al. The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma. Mol Oncol. 2022;16(3):565-93. [DOI:10.1002/1878-0261.13034] [PMID] [PMCID]
19. Li P, Ma X, Gu X. The essential roles of lncRNAs/PI3K/AKT axis in gastrointestinal tumors. Front Cell Dev Biol. 2024;12:1442193. [DOI:10.3389/fcell.2024.1442193] [PMID] [PMCID]
20. Xiao Y, Xia Y, Wang Y, Xue C. Pathogenic roles of long noncoding RNAs in melanoma: implications in diagnosis and therapies. Genes Dis. 2023;10(1):113-25. [DOI:10.1016/j.gendis.2021.08.007] [PMID] [PMCID]
21. Chen X, Dong H, Liu S, Yu L, Yan D, Yao X, et al. Long noncoding RNA MHENCR promotes melanoma progression via regulating miR-425/489-mediated PI3K-Akt pathway. Am J Transl Res. 2017;9(1):90.
22. Zhu J, Deng J, Zhang L, Zhao J, Zhou F, Liu N, et al. Reconstruction of lncRNA-miRNA-mRNA network based on competitive endogenous RNA reveals functional lncRNAs in skin cutaneous melanoma. BMC Cancer. 2020;20(1):938. [DOI:10.1186/s12885-020-07302-5]
23. Ghafouri-Fard S, Gholipour M, Taheri M. MicroRNA signature in melanoma: biomarkers and therapeutic targets. Front Oncol. 2021;11:608987. [DOI:10.3389/fonc.2021.608987] [PMID] [PMCID]
24. Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther. 2021;6(1):424. [DOI:10.1038/s41392-021-00827-6] [PMID] [PMCID]
25. Rafiepoor H, Ghorbankhanloo A, Soleimani Dorcheh S, Angouraj Taghavi E, Ghanadan A, Shirkoohi R, et al. Diagnostic power of microRNAs in melanoma: integrating machine learning for enhanced accuracy and pathway analysis. J Cell Mol Med. 2025;29(2):e70367. [DOI:10.1111/jcmm.70367] [PMID] [PMCID]
26. Gajos-Michniewicz A, Czyz M. Role of miRNAs in melanoma metastasis. Cancers. 2019;11(3):326. [DOI:10.3390/cancers11030326] [PMID] [PMCID]
27. Liu P, Hu Y, Ma L, Du M, Xia L, Hu Z. miR-425 inhibits melanoma metastasis through repression of PI3K-Akt pathway by targeting IGF-1. Biomed Pharmacother. 2015;75:51-57. [DOI:10.1016/j.biopha.2015.08.010] [PMID]
28. Shahbazi R, Davoodi H, Esmaeili S. The anticancer effects of flavonoids: involvement of PI3K/Akt signaling pathway. Iranian J Nutr Sci Food Technol. 2013;7 (1):1-10.
29. Jiang M, Zhang K, Zhang Z, Zeng X, Huang Z, Qin P, et al. PI3K/AKT/mTOR axis in cancer: From pathogenesis to treatment. Med Comm. 2025;6(8):e70295. [DOI:10.1002/mco2.70295] [PMID] [PMCID]
30. Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. Signal Trans Duct Target Therapy. 2021;6 (1):424. [DOI:10.1038/s41392-021-00827-6] [PMID] [PMCID]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb